Literature DB >> 31830585

Validation of four single-item patient-reported assessments of sleep in adult atopic dermatitis patients.

Donald Lei1, Muhammad Yousaf1, Sherief R Janmohamed1, Paras P Vakharia2, Rishi Chopra3, Rajeev Chavda4, Sylvie Gabriel4, Ryan Sacotte5, Kevin R Patel6, Vivek Singam7, Supriya Immaneni1, Robert Kantor3, Derek Y Hsu8, Jonathan I Silverberg9.   

Abstract

BACKGROUND: The optimal approaches for monitoring sleep disturbances in adults with atopic dermatitis (AD) is not established. Multiple patient-reported outcome measures for AD and itch have sleep-related items. These items have not been validated previously.
OBJECTIVE: Assess the measurement properties of sleep-related items from the Patient-Oriented Eczema Measure (POEM), SCORing AD (SCORAD), 5-dimensions of itch (5D), and ItchyQOL in adults with AD.
METHODS: We performed a prospective dermatology practice-based study using questionnaires and evaluation by a dermatologist (n = 115).
RESULTS: There was modest overlap and weak-moderate concordance of responses to the different assessments. Regarding concurrent validity, POEM-sleep, SCORAD-sleep, 5D-sleep, and ItchyQOL-sleep showed moderate correlations with each other. Regarding convergent validity, all items showed moderate correlation with total POEM, but weak correlations with Eczema Area and Severity Index (EASI), objective and total SCORAD, moderate to strong correlations with mean ItchyQOL and Dermatology Life Quality Index (DLQI), but poor or no significant correlation with Numeric Rating Scale (NRS) for worst or average itch. Regarding discriminant validity, all items showed significant and stepwise increases with increasing self-reported and physician-reported AD severity (Kruskal-Wallis, P < .01 for all). Floor effects were observed for POEM-sleep (n = 53, 46.1%), SCORAD-sleep (n = 28, 24.4%), 5D-sleep (n = 41, 35.7%), and ItchyQOL-sleep (n = 33, 28.7%); no ceiling effects were observed. Change in sleep-related item scores showed moderate strong correlations with change in POEM, 5Ditch, mean ItchyQOL, DLQI, objective and total SCORAD, and EASI, but inconsistent correlations with change of itch severity.
CONCLUSION: Sleep-related items from POEM, SCORAD, 5D and ItchyQOL showed good validity and responsiveness to monitor sleep disturbances in adult AD patients.
Copyright © 2019 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2019        PMID: 31830585     DOI: 10.1016/j.anai.2019.12.002

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  5 in total

1.  Effect of Vitamin D Serum Levels and Supplementation on Atopic Dermatitis: A Systematic Review and Meta-analysis.

Authors:  Jing Chun Ng; Yik Weng Yew
Journal:  Am J Clin Dermatol       Date:  2022-03-05       Impact factor: 7.403

Review 2.  Burden of Atopic Dermatitis in Adults and Adolescents: a Systematic Literature Review.

Authors:  Ahmad N Fasseeh; Baher Elezbawy; Nada Korra; Mohamed Tannira; Hala Dalle; Sandrine Aderian; Sherif Abaza; Zoltán Kaló
Journal:  Dermatol Ther (Heidelb)       Date:  2022-10-05

Review 3.  Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies.

Authors:  Fatima Bawany; Carrie A Northcott; Lisa A Beck; Wilfred R Pigeon
Journal:  J Allergy Clin Immunol Pract       Date:  2020-12-13

4.  Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials.

Authors:  L A Beck; J I Silverberg; E L Simpson; G Yosipovitch; L Eckert; I Guillemin; Z Chen; M Ardeleanu; S Plaum; N Graham; M Ruddy; G Pirozzi; A Gadkari
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-09-07       Impact factor: 6.166

5.  Psychometric validation and responder definition of the sleep disturbance numerical rating scale in moderate-to-severe atopic dermatitis.

Authors:  J Puelles; F Fofana; D Rodriguez; J I Silverberg; A Wollenberg; C Dias Barbosa; M Vernon; R Chavda; S Gabriel; C Piketty
Journal:  Br J Dermatol       Date:  2021-11-17       Impact factor: 11.113

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.